Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
MWN-AI** Summary
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company, reported its financial results and business highlights for the third quarter of 2025, revealing significant advancements in its work on therapies targeting oncogene-amplified cancers through extrachromosomal DNA (ecDNA) biology. President and CEO Zachary Hornby emphasized the company's commitment to developing innovative treatments, citing ongoing enrollment in the combination arm of the Phase 1/2 POTENTIATE trial for BBI-355 and BBI-825. The company anticipates sharing initial proof-of-concept data within its current cash runway.
Boundless Bio is also on track for the investigational new drug (IND) submission for its novel, orally bioavailable Kinesin degrader, BBI-940, which is expected to enter a first-in-human Phase 1 clinical trial in the first half of 2026. The company has $118 million in cash, providing the financial runway to support operations through the first half of 2028.
Financially, Boundless Bio reported R&D expenses of $10.7 million for Q3 2025, significantly lower than the $14.1 million reported the previous year. General and administrative expenses remained relatively stable, totaling $4.5 million for the quarter. The net loss for the third quarter was $13.9 million, an improvement from the $16.5 million loss recorded in Q3 2024.
Overall, Boundless Bio continues to make strides in its ecDNA-focused pipeline, aiming to address an urgent need in cancer therapeutics. The ongoing trials and upcoming IND submission showcase the company’s dedication to potentially transformative treatments for patients with oncogene-amplified tumors while managing costs effectively.
MWN-AI** Analysis
Boundless Bio (Nasdaq: BOLD) has reported its third-quarter 2025 financial results, showcasing its ongoing commitment to developing groundbreaking therapies for oncogene-amplified cancers. Key highlights reveal a continued focus on R&D with a cash position of $118 million, projected to support operations through 2028—sufficient to cover expected proof-of-concept data for its leading candidates, BBI-355 and BBI-825.
The ongoing enrollment in the POTENTIATE trial is a crucial milestone and presents an opportunity for investors. The combination of BBI-355 and BBI-825 targets a significant unmet medical need, and initial proof-of-concept clinical data expected within the existing cash runway timeline could act as a turning point for the stock. Clinical outcomes will be pivotal; positive results may catalyze significant share price appreciation as investor sentiment towards biopharma stocks is highly responsive to clinical trial data.
Moreover, the anticipated investigational new drug (IND) submission for BBI-940, a novel Kinesin degrader set to enter first-in-human trials in early 2026, adds an extra layer of excitement. This program’s potential as a first-in-class therapy could elevate Boundless Bio’s profile within oncology, drawing interest from both analysts and institutional investors.
Investor caution is warranted given the inherent risks in clinical-stage companies. However, a tightened R&D expense structure suggests management's prudent financial stewardship, as recent quarterly expenses declined from $14.1 million in 2024 to $10.7 million in 2025. This decreasing burn rate, coupled with a consistent net loss reduction from $16.5 million to $13.9 million, reflects a strategic approach to extending cash runway without sacrificing growth potential.
In summary, Boundless Bio presents an intriguing proposition for investors focused on oncology breakthroughs. The upcoming clinical developments, coupled with a solid cash position, support a cautiously optimistic outlook. Investors may consider accumulating shares in anticipation of clinical trial milestones that could drive valuation upward in the coming 12 months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial
Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026
$118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended September 30, 2025.
“We are advancing a pipeline rooted in tumor-enabling ecDNA biology to bring forward innovative therapies for patients with oncogene-amplified cancers,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Enrollment is underway in the BBI-355/BBI-825 combination arm of the POTENTIATE trial, and we are excited to advance BBI-940, our novel, orally bioavailable Kinesin degrader into the clinic in the first half of 2026, as we work to deliver a meaningful impact for both patients and shareholders.”
Research and Development Highlights and Upcoming Milestones
POTENTIATE clinical trial of BBI-355 and BBI-825
- The combination arm of the Phase 1/2 POTENTIATE trial evaluating BBI-355 and BBI-825 in oncogene-amplified cancers is actively enrolling. The Company expects to deliver initial proof-of-concept clinical data within its existing cash runway timeline.
BBI-940 novel Kinesin program targeting ecDNA segregation and inheritance
- The Company expects to submit an investigational new drug (IND) application for BBI-940 and initiate a first-in-human Phase 1 clinical trial in the first half of 2026.
- Initial proof-of-concept clinical data are expected within the Company’s existing cash runway timeline.
Third Quarter 2025 Financial Results
- Cash Position: Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025.
- Research and Development (R&D) Expenses: R&D expenses were $10.7 million for the third quarter of 2025, compared to $14.1 million for the same period in 2024.
- General and Administrative (G&A) Expenses: G&A expenses were $4.5 million for the third quarter of 2025, compared to $4.6 million for the same period in 2024.
- Net Loss: Net loss totaled $13.9 million for the third quarter of 2025, compared to $16.5 for the same period in 2024.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification, observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidates (ecDTx), BBI-355, an oral, selective inhibitor of checkpoint kinase 1 (CHK1), and BBI-825, an oral, selective inhibitor of ribonucleotide reductase (RNR). These compounds are being evaluated in combination in patients with oncogene amplified cancers in the Company’s Phase 1/2 POTENTIATE clinical trial. Boundless Bio is conducting IND-enabling studies of another ecDTx, BBI-940, a potentially first-in-class, orally bioavailable, selective Kinesin degrader. Boundless Bio is headquartered in San Diego, CA.
For more information, visit www.boundlessbio.com and follow us on LinkedIn and X .
Forward-Looking Statements
Boundless Bio (the Company) cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “would,” “target,” or “will” or the negative of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. Forward-looking statements include statements regarding: the Company’s expected cash runway and the sufficiency thereof to fund operations through anticipated proof-of-concept clinical data readouts for each of its therapeutic programs; the timing of expected data readouts; submission of an IND application to the U.S. Food and Drug Administration (FDA) for and initiation of a Phase 1 clinical trial of BBI-940, and the timing thereof; the potential safety and therapeutic benefits of the Company’s ecDTx in treating patients with oncogene amplified cancers, including whether the combination of BBI-355 and BBI-825 will provide therapeutic benefit without overlapping toxicity; and the Company’s potential to deliver a meaningful impact for patients and shareholders. The Company’s actual results and performance may differ materially from those expressed or implied in any forward-looking statement due to substantial known and unknown risks and uncertainties, including, without limitation: the Company is early in its development efforts and its approach to discover and develop ecDTx to treat oncogene amplified cancers is novel and unproven; clinical and preclinical development of therapeutics involves a lengthy and expensive process with inherently uncertain timelines and outcomes; the Company’s ecDTx may not achieve favorable results in ongoing or future clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; potential delays in the commencement, enrollment, data readouts or completion of clinical trials or preclinical studies or submission of an IND; the Company’s dependence on third parties in connection with clinical trials, preclinical studies, and manufacturing; unfavorable results from clinical trials or preclinical studies; the Company may expend its limited resources to pursue a particular ecDTx or combination therapy and fail to capitalize on ecDTx with greater development or commercial potential; unexpected adverse side effects or inadequate efficacy of the Company’s ecDTx that may limit their development, regulatory approval, and/or commercialization; the potential for the Company’s programs and prospects to be negatively impacted by developments relating to its competitors, including the results of studies or regulatory determinations relating to its competitors; regulatory and healthcare reform developments in the United States and foreign countries; disruptions in the FDA’s ability to perform routine activities or function in the normal course; the Company may use its capital resources sooner than it expects and be unable to obtain necessary additional funding when needed, on acceptable terms, or at all; the Company’s ability to obtain, maintain, defend, and enforce patent or other intellectual property protection for its ecDTx and technology; the potential for third-party claims of intellectual property infringement, misappropriation, or other violations against the Company; macroeconomic and geopolitical events and conditions, including international trade policies and tariffs; and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2024, the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Contacts:
James Lee, Boundless Bio, Inc.
jlee@boundlessbio.com
Renee Leck, THRUST Strategic Communications
renee@thrustsc.com
Media Contact:
Carly Scaduto
carly@carlyscadutoconsulting.com
| BOUNDLESS BIO, INC. | |||||||||||||||
| Unaudited Financial Information | |||||||||||||||
| Condensed Statements of Operations Data: | Three months ended September 30 | Nine months ended September 30 | |||||||||||||
| (In thousands, except per share amounts) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 10,673 | $ | 14,089 | $ | 35,028 | $ | 41,953 | |||||||
| General and administrative | 4,475 | 4,626 | 14,522 | 13,036 | |||||||||||
| Total operating expenses | 15,148 | 18,715 | 49,550 | 54,989 | |||||||||||
| Loss from operations | (15,148 | ) | (18,715 | ) | (49,550 | ) | (54,989 | ) | |||||||
| Other income, net: | |||||||||||||||
| Interest income | 1,269 | 2,174 | 4,240 | 5,977 | |||||||||||
| Other income/ (expense), net | - | 32 | (2 | ) | 97 | ||||||||||
| Total other income, net | 1,269 | 2,206 | 4,238 | 6,074 | |||||||||||
| Net loss | $ | (13,879 | ) | $ | (16,509 | ) | $ | (45,312 | ) | $ | (48,915 | ) | |||
| Net loss per share, basic and diluted | $ | (0.62 | ) | $ | (0.74 | ) | $ | (2.03 | ) | $ | (3.22 | ) | |||
| Weighted-average shares used in calculation | 22,386 | 22,254 | 22,347 | 15,204 | |||||||||||
| Condensed Balance Sheet Data: | September 30, | December 31, | |||||||||||||
| (In thousands) | 2025 | 2024 | |||||||||||||
| Cash, cash equivalents, and short-term investments | $ | 117,570 | $ | 152,114 | |||||||||||
| Total assets | $ | 168,721 | $ | 206,409 | |||||||||||
| Total liabilities | $ | 58,552 | $ | 55,767 | |||||||||||
| Accumulated deficit | $ | (246,784 | ) | $ | (201,472 | ) | |||||||||
| Total stockholders’ equity | $ | 110,169 | $ | 150,642 | |||||||||||
| Working capital (1) | $ | 108,311 | $ | 146,255 | |||||||||||
| __________ | |||||||||||||||
| (1) We define working capital as current assets less current liabilities. |
FAQ**
How will the ongoing enrollment in the BBI-355/BBI-825 combination arm of the POTENTIATE trial impact Audentes Therapeutics Inc. BOLD's timeline for proof-of-concept data and subsequent clinical decisions?
What strategies does Audentes Therapeutics Inc. BOLD have in place to ensure robust patient recruitment for the BBI-355/BBI-8combination arm of the POTENTIATE trial?
Can you provide insight on how the successful enrollment of the POTENTIATE trial may influence the market perception and stock performance of Audentes Therapeutics Inc. BOLD?
What key indicators is Audentes Therapeutics Inc. BOLD monitoring in the ongoing POTENTIATE trial to gauge the potential success of the BBI-355 and BBI-825 combination therapy?
**MWN-AI FAQ is based on asking OpenAI questions about Audentes Therapeutics Inc. (NASDAQ: BOLD).
NASDAQ: BOLD
BOLD Trading
-2.19% G/L:
$1.115 Last:
18,055 Volume:
$1.1302 Open:
